Carisma Therapeutics (CARM) Competitors $0.87 +0.01 (+0.83%) (As of 09:15 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends CARM vs. CTSO, TXMD, AWH, SNSE, XGN, NLTX, SGMT, ABOS, PBYI, and BDTXShould you be buying Carisma Therapeutics stock or one of its competitors? The main competitors of Carisma Therapeutics include Cytosorbents (CTSO), TherapeuticsMD (TXMD), Aspira Women's Health (AWH), Sensei Biotherapeutics (SNSE), Exagen (XGN), Neoleukin Therapeutics (NLTX), Sagimet Biosciences (SGMT), Acumen Pharmaceuticals (ABOS), Puma Biotechnology (PBYI), and Black Diamond Therapeutics (BDTX). These companies are all part of the "medical" sector. Carisma Therapeutics vs. Cytosorbents TherapeuticsMD Aspira Women's Health Sensei Biotherapeutics Exagen Neoleukin Therapeutics Sagimet Biosciences Acumen Pharmaceuticals Puma Biotechnology Black Diamond Therapeutics Carisma Therapeutics (NASDAQ:CARM) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, community ranking, earnings, dividends and profitability. Is CARM or CTSO more profitable? Cytosorbents has a net margin of -49.47% compared to Carisma Therapeutics' net margin of -314.78%. Cytosorbents' return on equity of -118.54% beat Carisma Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Carisma Therapeutics-314.78% -957.20% -96.39% Cytosorbents -49.47%-118.54%-42.31% Do insiders & institutionals believe in CARM or CTSO? 44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 32.9% of Cytosorbents shares are owned by institutional investors. 12.6% of Carisma Therapeutics shares are owned by insiders. Comparatively, 6.6% of Cytosorbents shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility and risk, CARM or CTSO? Carisma Therapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Does the MarketBeat Community favor CARM or CTSO? Cytosorbents received 423 more outperform votes than Carisma Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Carisma Therapeutics an outperform vote while only 75.87% of users gave Cytosorbents an outperform vote. CompanyUnderperformOutperformCarisma TherapeuticsOutperform Votes14100.00% Underperform VotesNo VotesCytosorbentsOutperform Votes43775.87% Underperform Votes13924.13% Do analysts rate CARM or CTSO? Carisma Therapeutics currently has a consensus price target of $7.00, suggesting a potential upside of 711.69%. Cytosorbents has a consensus price target of $2.00, suggesting a potential upside of 118.36%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Carisma Therapeutics is more favorable than Cytosorbents.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Cytosorbents 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has preferable valuation and earnings, CARM or CTSO? Cytosorbents has higher revenue and earnings than Carisma Therapeutics. Cytosorbents is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCarisma Therapeutics$20.27M1.78-$86.88M-$1.56-0.55Cytosorbents$36.35M1.38-$28.51M-$0.36-2.54 Does the media favor CARM or CTSO? In the previous week, Cytosorbents had 2 more articles in the media than Carisma Therapeutics. MarketBeat recorded 6 mentions for Cytosorbents and 4 mentions for Carisma Therapeutics. Carisma Therapeutics' average media sentiment score of 0.20 beat Cytosorbents' score of -0.24 indicating that Carisma Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Carisma Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cytosorbents 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryCarisma Therapeutics beats Cytosorbents on 10 of the 18 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get Carisma Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CARM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CARM vs. The Competition Export to ExcelMetricCarisma TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.01M$6.45B$5.04B$8.81BDividend YieldN/A8.11%5.16%4.07%P/E Ratio-0.5510.78130.5317.82Price / Sales1.78243.701,183.8674.55Price / CashN/A22.1633.6132.53Price / Book1.315.474.684.68Net Income-$86.88M$153.61M$119.23M$226.08M7 Day Performance-8.15%-2.00%-1.83%-1.04%1 Month Performance-11.77%-7.46%-3.61%1.04%1 Year Performance-64.66%31.82%31.74%26.28% Carisma Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CARMCarisma Therapeutics3.3239 of 5 stars$0.87+0.8%$7.00+705.0%-64.7%$36.31M$14.92M-0.5620CTSOCytosorbents1.2769 of 5 stars$0.92-4.2%$2.00+118.4%-34.6%$50.08M$36.35M0.00186Analyst ForecastGap DownTXMDTherapeuticsMD0.6981 of 5 stars$1.34+3.1%N/A-54.1%$15.45M$1.30M0.00420Analyst ForecastGap UpAWHAspira Women's Health1.533 of 5 stars$0.77+5.5%$4.40+471.4%-78.5%$12.37M$9.15M0.00110Analyst ForecastGap UpSNSESensei Biotherapeutics4.6934 of 5 stars$0.50+4.2%$4.33+770.1%-20.0%$12.07MN/A0.0040News CoverageXGNExagen4.7894 of 5 stars$4.78+13.8%$7.00+46.4%+169.2%$84.32M$52.55M0.00220Analyst RevisionGap UpNLTXNeoleukin TherapeuticsN/A$15.33-11.0%N/A+30.5%$144.07MN/A-4.9390High Trading VolumeSGMTSagimet Biosciences2.1861 of 5 stars$4.65+2.9%$21.60+364.5%+50.2%$142.62M$2M0.008ABOSAcumen Pharmaceuticals2.6635 of 5 stars$2.37-0.8%$9.00+279.7%+0.4%$142.39MN/A0.0051Analyst RevisionPBYIPuma Biotechnology4.4141 of 5 stars$2.89+1.8%$7.00+142.2%-27.0%$141.87M$235.60M5.92185Analyst ForecastPositive NewsBDTXBlack Diamond Therapeutics2.8436 of 5 stars$2.49+2.5%$15.50+522.5%+8.0%$140.88MN/A0.0090Positive News Related Companies and Tools Related Companies Cytosorbents Alternatives TherapeuticsMD Alternatives Aspira Women's Health Alternatives Sensei Biotherapeutics Alternatives Exagen Alternatives Neoleukin Therapeutics Alternatives Sagimet Biosciences Alternatives Acumen Pharmaceuticals Alternatives Puma Biotechnology Alternatives Black Diamond Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CARM) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Carisma Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
